Front. Pharmacol.Frontiers in PharmacologyFront. Pharmacol.1663-9812Frontiers Media S.A.138569810.3389/fphar.2024.1385698PharmacologyCorrectionCorrigendum: Precision medicine: a new era for inner ear diseasesTavazzani et al.10.3389/fphar.2024.1385698TavazzaniElisa12*†SpaiardiPaolo34*†ContiniDonatella5SanciniGiulio67‡RussoGiancarlo8‡MasettoSergio8‡1Department of Molecular Medicine, University of Pavia, Pavia, Italy2ICS-Maugeri IRCCS, Pavia, Italy3Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, Pavia, Italy4Istituto Nazionale di Fisica Nucleare, Sezione di Pavia, Pavia, Italy5Department of Anatomy and Cell Biology, University of Illinois at Chicago, Chicago, IL, United States6Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy7Nanomedicine Center, Neuroscience Center, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy8Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
Approved by:Frontiers Editorial Office, Frontiers Media SA, Switzerland
*Correspondence: Elisa Tavazzani, elisa.tavazzani@unipv.it; Paolo Spaiardi, paolo.spaiardi@unipv.it
These authors have contributed equally to this work and share first authorship
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Precision medicine: a new era for inner ear diseases by Tavazzani E, Spaiardi P, Contini D, Sancini G, Russo G and Masetto S (2024). Front. Pharmacol. 15:1328460. doi: 10.3389/fphar.2024.1328460vestibulecochleainner earnanoparticlesmicroneedlesprecision medicinesection-at-acceptancePharmacogenetics and Pharmacogenomics
In the published article, there was an error in the Funding statement. The CUP numbers were missed. “The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The fee of this publication is supported by the following grants: FIS. SPAIA.PRIN 2022; PRIN 2022 funded by the European Union–Next-Generation EU, PRIN 20228AAJRL; PRIN 2022 funded by the European Union–Next-Generation EU, 2023-ATEQC-0026—multifunctional nanocarriers as advanced biomaterials for targeted and therapeutic RNA delivery [MixnMatch] financed to: SP, MS, and SG respectively” and include original text. The correct Funding statement appears below.
Funding
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. The fee of this publication is supported by the following grants: FIS. SPAIA.PRIN 2022; PRIN 2022 funded by the European Union–Next-Generation EU, CUP F53D23006030001; PRIN 20228AAJRL; PRIN 2022 funded by the European Union–Next-Generation EU, CUP F53D23005930006; 2023-ATEQC-0026—multifunctional nanocarriers as advanced biomaterials for targeted and therapeutic RNA delivery [MixnMatch] financed to: SP, MS, and SG respectively.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.